|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.07.26 - 12:51
|
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 (Business Wire)
|
|
|
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Aug. 4. During the call, company executives will provide an overview of Merck's performance for the quarter.
Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com.
All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought...
|
|
|
01.07.26 - 12:39
|
Merck & Co Aktie: Hoffnungen auf neuen Lungenkrebs-Blockbuster (Aktiencheck)
|
|
|
Charlotte (www.aktiencheck.de) - Merck & Co-Aktienanalyse der Bank of America (BofA):
BofA habe das Kursziel für die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) von 130 auf 141 USD angehoben und das "buy"-Rating bestätigt. Als Begründung für das höhere Kursziel würden die Analysten auf eine verbesserte Bewertung des Pharmasektors verweisen, die zu einer Neubewertung der Branche geführt habe. [mehr]...
|
|
|
|
|
29.06.26 - 16:45
|
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
|
|
|
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?...
|
|
|
|
|
26.06.26 - 18:06
|
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? (24/7 Wall St.)
|
|
|
Shares of Moderna (NASDAQ:MRNA) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer. Intraday, MRNA stock hit a new 52-week high of $69.29. The rally easily outpaces peer vaccine makers. Merck (NYSE:MRK) stock is up 2% to $128, while Pfizer (NYSE:PFE) stock trades up 2% ... Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
